Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.22 (
cdc2
)
8,319
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cyclin T2a was recently identified as one of the regulatory subunits of the cdk-cyclin complex P-TEFb, the most studied positive factor in the regulation of transcription elongation. By fluorescent in situ hybridization (FISH), the gene codifying for
cyclin T2a
has been mapped on human chromosome 2q21. This locus also has been linked to different forms of myopathy. By use of a new specific antiserum raised against
cyclin T2a
, the immunohistochemical pattern of expression of
cyclin T2a
in human tissues has been examined and compared to that of cyclin T1, described in the previous report. The observation that immunohistochemical expression of
cyclin T2a
was high in skeletal muscle cells, whereas it was undetectable in two cases of centronuclear myopathy, together with its chromosomal location, suggests an involvement of the
cdk9
-
cyclin T2a
complex in this disease.
...
PMID:Cyclin T2a gene maps on human chromosome 2q21. 1137 16
Myogenic transcription is repressed in myoblasts by serum-activated cyclin-dependent kinases, such as
cdk2
and
cdk4
. Serum withdrawal promotes muscle-specific gene expression at least in part by down-regulating the activity of these cdks. Unlike the other cdks,
cdk9
is not serum- or cell cycle-regulated and is instead involved in the regulation of transcriptional elongation by phosphorylating the carboxyl-terminal domain (CTD) of RNA polymerase II. While ectopic expression of
cdk2
together with its regulatory subunits (cyclins E and A) inhibits myogenic transcription, overproduction of
cdk9
and its associated cyclin (
cyclin T2a
) strengthens MyoD-dependent transcription and stimulates myogenic differentiation in both MyoD-converted fibroblasts and C2C12 muscle cells. Conversely, inhibition of
cdk9
activity by a dominant negative form (cdk9-dn) represses the myogenic program. Cdk9, cyclinT2 and MyoD can be detected in a multimeric complex in C2C12 cells, with the minimal
cdk9
-binding region of MyoD mapping within 101-161 aa of the bHLH region. Finally,
cdk9
can phosphorylate MyoD in vitro, suggesting the possibility that
cdk9
/cycT2a regulation of muscle differentiation includes the direct enzymatic activity of the kinase on MyoD.
...
PMID:Activation of MyoD-dependent transcription by cdk9/cyclin T2. 1203 70
Myocyte differentiation is due to transcription of genes that characterize the phenotypic and biochemical identity of differentiated muscle cells. These are the myogenic regulatory factors (MRFs) MyoD, Myf5, myogenin and MRF4. Overexpression of cdk/cyclins has been reported to inhibit the activity of MyoD and prevent myogenic differentiation by different modalities. Unlike other cdk/cyclin complexes, overexpression of
cdk9
/
cyclin T2a
, enhances MyoD function and promotes myogenic differentiation. In addition,
cyclin T2a
interacting with a novel partner, PKN alpha, is able to strongly enhance the expression of myogenic differentiation markers, such as myogenin and Myosin Heavy Chain. So,
cyclin T2a
could stimulate myogenic differentiation interacting with different kinase partners Cdk9 or PKN alpha in a synergistic or antagonistic way.
...
PMID:Involvement of cdks and cyclins in muscle differentiation. 1658 81
Cyclin-dependent kinase 9 (Cdk9) is a
cdc2
-like serine/threonine kinase. The so-called Cdk9-related pathway comprises two Cdk9 isoforms (Cdk9-42 and Cdk9-55), cyclin T1,
cyclin T2a
,
cyclin T2b
and cyclin K. The association between Cdk9 and one of its cyclin partners forms a heterodimer, which is the main component of the positive transcription elongation factor (P-TEFb). The latter stabilizes the elongation process of RNA polymerase II (polII) transcripts. Through the control of RNA polII-mediated gene expression, the Cdk9-related pathway performs an important role in several biological processes, such as cell growth, proliferation, protection from apoptosis and differentiation. Incidentally, the P-TEFb that contains the heterodimer Cdk9-cyclin T1 is also critical for HIV-1 and HIV-2 replication in human cells. A deregulation in the Cdk9-related pathway is associated with various types of human malignancies and cardiomyocytes hypertrophy. On these grounds, the characterization of Cdk9-related pathway deregulation might have a two-fold purpose: (1) the development of novel kinase inhibitors for the treatment of cancer, AIDS and cardiac hypertrophy and (2) a better understanding of the pathogenesis and progression of these maladies.
...
PMID:Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases. 1902 9